人类免疫缺陷病毒1型B和C亚型之间的分支特异性差异：gp120的C3-V4区域的多样性及相关性
Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.
作者信息
Gnanakaran S, Lang Dorothy, Daniels Marcus, Bhattacharya Tanmoy, Derdeyn Cynthia A, Korber Bette
机构信息
Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
出版信息
J Virol. 2007 May;81(9):4886-91. doi: 10.1128/JVI.01954-06. Epub 2006 Dec 13.
Abstract
Current knowledge of human immunodeficiency virus type 1 envelope (Env) glycoprotein structure and function is based on studies of clade B viruses. We present evidence of sequence and structural differences in viral glycoprotein gp120 between clades B and C. In clade C, the C3 region alpha2-helix exhibits high sequence entropy at the polar face but maintains its amphipathicity, whereas in clade B it accommodates hydrophobic residues. The V4 hypervariable domain in clade C is shorter than that in clade B. Generally, shorter V4 loops are incompatible with a glycine occurring in the alpha2-helix in clade C, an intriguing association that could be exploited to inform Env immunogen design.
摘要
目前对1型人类免疫缺陷病毒包膜（Env）糖蛋白结构和功能的了解基于B亚型病毒的研究。我们提供了B亚型和C亚型病毒糖蛋白gp120在序列和结构上存在差异的证据。在C亚型中，C3区域的α2螺旋在极性面表现出高序列熵，但保持其两亲性，而在B亚型中它容纳疏水残基。C亚型中的V4高变区比B亚型中的短。一般来说，较短的V4环与C亚型α2螺旋中出现的甘氨酸不兼容，这一有趣的关联可用于指导Env免疫原设计。
相似文献
1
Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.
J Virol. 2007 May;81(9):4886-91. doi: 10.1128/JVI.01954-06. Epub 2006 Dec 13.
2
Human immunodeficiency virus type 1 clade A and D neurotropism: molecular evolution, recombination, and coreceptor use.
Virology. 2001 Apr 25;283(1):19-30. doi: 10.1006/viro.2001.0876.
3
Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.
J Virol. 2007 Jun;81(11):5658-68. doi: 10.1128/JVI.00257-07. Epub 2007 Mar 14.
4
Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.
Vaccine. 2006 Jun 5;24(23):4995-5002. doi: 10.1016/j.vaccine.2006.03.083. Epub 2006 Apr 18.
5
Molecular and phylogenetic characterization of HIV variants in Italian primary HIV infections (PHI): identification of non-B subtype variants.
J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):44-8.
6
Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda.
AIDS Res Hum Retroviruses. 1994 Nov;10(11):1543-50. doi: 10.1089/aid.1994.10.1543.
7
HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity.
Sci Rep. 2015 Jun 9;5:11130. doi: 10.1038/srep11130.
8
Low complexity regions (LCRs) contribute to the hypervariability of the HIV-1 gp120 protein.
J Theor Biol. 2013 Dec 7;338:80-6. doi: 10.1016/j.jtbi.2013.08.039. Epub 2013 Sep 8.
9
Phylogenetic analysis of human immunodeficiency virus 1 in Ghana.
Acta Virol. 1997 Feb;41(1):51-4.
10
HIV type 1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity.
AIDS Res Hum Retroviruses. 1998 Mar 1;14(4):319-27. doi: 10.1089/aid.1998.14.319.
引用本文的文献
1
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
PLoS Pathog. 2023 Oct 30;19(10):e1011601. doi: 10.1371/journal.ppat.1011601. eCollection 2023 Oct.
2
Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.
Viruses. 2023 Aug 13;15(8):1732. doi: 10.3390/v15081732.
3
Consequences of HIV infection in the bone marrow niche.
Front Immunol. 2023 Jul 11;14:1163012. doi: 10.3389/fimmu.2023.1163012. eCollection 2023.
4
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?
FEMS Microbiol Rev. 2023 Jan 16;47(1). doi: 10.1093/femsre/fuac040.
5
A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.
PLoS Pathog. 2022 May 3;18(5):e1010488. doi: 10.1371/journal.ppat.1010488. eCollection 2022 May.
6
Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
PLoS One. 2021 May 24;16(5):e0251969. doi: 10.1371/journal.pone.0251969. eCollection 2021.
7
Opioid and neuroHIV Comorbidity - Current and Future Perspectives.
J Neuroimmune Pharmacol. 2020 Dec;15(4):584-627. doi: 10.1007/s11481-020-09941-8. Epub 2020 Sep 2.
8
Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels.
mBio. 2020 Jun 9;11(3):e00126-20. doi: 10.1128/mBio.00126-20.
9
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00110-19. Print 2019 Jun.
10
Limitations of the International HIV Dementia Scale in the current era.
AIDS. 2018 Nov 13;32(17):2477-2483. doi: 10.1097/QAD.0000000000001968.
本文引用的文献
1
Founder effects in the assessment of HIV polymorphisms and HLA allele associations.
Science. 2007 Mar 16;315(5818):1583-6. doi: 10.1126/science.1131528.
2
Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.
J Virol. 2007 Jun;81(11):5658-68. doi: 10.1128/JVI.00257-07. Epub 2007 Mar 14.
3
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.
J Virol. 2006 Jul;80(13):6525-33. doi: 10.1128/JVI.02658-05.
4
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.
J Virol. 2006 Jan;80(2):835-44. doi: 10.1128/JVI.80.2.835-844.2006.
5
Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.
J Virol. 2005 May;79(10):6528-31. doi: 10.1128/JVI.79.10.6528-6531.2005.
6
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.
J Virol. 2005 May;79(10):6523-7. doi: 10.1128/JVI.79.10.6523-6527.2005.
7
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.
J Exp Med. 2005 Mar 21;201(6):891-902. doi: 10.1084/jem.20041455.
8
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Science. 2004 Mar 26;303(5666):2019-22. doi: 10.1126/science.1093137.
9
Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes.
J Virol. 2004 Feb;78(4):1962-70. doi: 10.1128/jvi.78.4.1962-1970.2004.
10
Widespread adaptive evolution in the human immunodeficiency virus type 1 genome.
J Mol Evol. 2003 Aug;57(2):212-21. doi: 10.1007/s00239-003-2467-9.
Zotero 插件